NCT04902586 (ECTG001) is a NA clinical trial of TTFields in Glioma, sponsored by Zhongnan Hospital.

Who is sponsoring NCT04902586?

NCT04902586 is sponsored by Zhongnan Hospital.

What drugs are being tested in NCT04902586?

Interventions in NCT04902586: TTFields.

What condition does NCT04902586 study?

NCT04902586 studies Glioma, Glioblastoma.

Is NCT04902586 still recruiting?

NCT04902586 is currently status unknown. Last updated 26 May 2021.

Last reviewed 2021-05-26 · How we verify

NCT04902586: ECTG001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma

Status unknown NA Last updated 26 May 2021

What this trial tests

NA trial testing TTFields in Glioma in 30 participants. Status unknown.

Timeline

19 June 2021

Primary endpoint
19 December 2021

19 July 2022

Quick facts

Lead sponsor	Zhongnan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	19 June 2021
Primary completion	19 December 2021
Estimated completion	19 July 2022
Sites	1 location across China

Drugs / interventions tested

TTFields

Conditions studied

Glioma — all drugs for Glioma →
Glioblastoma — all drugs for Glioblastoma →

Sponsor

Zhongnan Hospital

Who can join

Adults 18 to 70, any sex, with Glioma or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TTFields has been approved by the FDA for the treatment of patients with glioblastoma multiforme. However, the clinical effect and safety of radiotherapy concurrent of TTFields is not definite. In this study, the investigators conduct a phase II clinical trial to evaluate the efficacy and safety of this strategy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution.
Liang T, Gu L, Kang X, Li J, et al · · 2024 · cited 13× · PMID 38890642 · DOI 10.1186/s12964-024-01602-0
Therapeutic potential of tumor treating fields for malignant brain tumors.
Zhou Y, Xing X, Zhou J, Jiang H, et al · · 2023 · cited 8× · PMID 36987739 · DOI 10.1002/cnr2.1813
Nuclear Mechanotransduction Across the Metastatic Cascade: Decoding Spatiotemporal Heterogeneity in Cancer Dissemination.
Song L, Liu J, Wang X, Zhang M, et al · · 2026 · PMID 41926644 · DOI 10.1002/advs.202523974

Verify or expand the search:

Other trials of TTFields

Trials testing the same drug.

NCT06136611 — Preoperative Preradiotherapy TTFields · NA · not yet recruiting
NCT04218019 — Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation · NA · withdrawn
NCT04717739 — TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study · unknown
NCT04492163 — Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM · Phase 2 · completed
NCT04689087 — A Prospective, Open-label, Single-arm Clinical Study · NA · unknown

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other Zhongnan Hospital trials

Trials by the same sponsor.

NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04902586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
Last refreshed: 26 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04902586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing